WallStSmart

Covista Inc. (CVSA)vsIhuman Inc (IH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Covista Inc. generates 122% more annual revenue ($1.89B vs $849.05M). CVSA leads profitability with a 13.4% profit margin vs 12.5%. IH trades at a lower P/E of 6.1x. CVSA earns a higher WallStSmart Score of 67/100 (B-).

CVSA

Strong Buy

67

out of 100

Grade: B-

Growth: 5.3Profit: 7.5Value: 8.3Quality: 5.0

IH

Hold

42

out of 100

Grade: D

Growth: 2.0Profit: 6.0Value: 6.3Quality: 8.0
Piotroski: 3/9Altman Z: 2.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CVSASignificantly Overvalued (N/A)

Margin of Safety

N/A

Fair Value

$97.23

Current Price

$113.08

$15.85 premium

UndervaluedFair: $97.23Overvalued
IHFair Value (-4.4%)

Margin of Safety

-4.4%

Fair Value

$1.97

Current Price

$1.73

$0.24 premium

UndervaluedFair: $1.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CVSA4 strengths · Avg: 8.0/10
PEG RatioValuation
0.818/10

Growing faster than its price suggests

P/E RatioValuation
16.1x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

IH3 strengths · Avg: 10.0/10
P/E RatioValuation
6.1x10/10

Attractively priced relative to earnings

Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Areas to Watch

CVSA1 concerns · Avg: 4.0/10
EPS GrowthGrowth
4.7%4/10

4.7% earnings growth

IH4 concerns · Avg: 2.5/10
Market CapQuality
$90.37M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Revenue GrowthGrowth
-14.1%2/10

Revenue declined 14.1%

EPS GrowthGrowth
-11.1%2/10

Earnings declined 11.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : CVSA

The strongest argument for CVSA centers on PEG Ratio, P/E Ratio, Price/Book. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.81 suggests the stock is reasonably priced for its growth.

Bull Case : IH

The strongest argument for IH centers on P/E Ratio, Price/Book, Debt/Equity.

Bear Case : CVSA

The primary concerns for CVSA are EPS Growth.

Bear Case : IH

The primary concerns for IH are Market Cap, Piotroski F-Score, Revenue Growth.

Key Dynamics to Monitor

CVSA profiles as a value stock while IH is a declining play — different risk/reward profiles.

CVSA carries more volatility with a beta of 0.73 — expect wider price swings.

CVSA is growing revenue faster at 12.4% — sustainability is the question.

Monitor EDUCATION & TRAINING SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CVSA scores higher overall (67/100 vs 42/100) and 12.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Covista Inc.

CONSUMER DEFENSIVE · EDUCATION & TRAINING SERVICES · USA

Covista Inc., provides healthcare education in the United States, Barbados, St. Kitts, and St. Maarten. The company is headquartered in Chicago, Illinois.

Ihuman Inc

CONSUMER DEFENSIVE · EDUCATION & TRAINING SERVICES · China

iHuman Inc. provides children's entertainment products and services to individual users, educational organizations and distributors in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.

Visit Website →

Want to dig deeper into these stocks?